title: Topical cream-based oxyresveratrol in the treatment of cutaneous HSV-1 infection in mice.
abstract: Anti-herpes simplex virus (HSV) activities of oxyresveratrol in vitro and topical administration in cutaneous HSV-1 infection in mice were examined. The inhibitory concentrations for 50% plaque formation (IC(50)) of oxyresveratrol against HSV-1 clinical isolates and HSV-2 clinical isolates were 20.9-29.5 and 22.2-27.5 μg/ml, respectively. In topical administration in cutaneous HSV-1 infection in mice, 2.5%, 5%, 10% and 20% oxyresveratrol in cream vehicle applied three times daily for 7 days after infection were evaluated and 10% and 20% oxyresveratrol cream were significantly effective in delaying the development of skin lesions and protection from death (P < 0.01). The concentration of 10% oxyresveratrol in cream was significantly more effective than that of 30% oxyresveratrol in vaseline applied three times daily (P < 0.01). Oxyresveratrol cream at 20% was as effective as 5% ACV cream applied three times daily (P < 0.01). Both 10% and 20% oxyresveratrol cream were as effective as that of 5% ACV cream applied two times daily (P > 0.05). Therapeutic efficacy of oxyresveratrol in cream vehicle was dose-dependent and the maximum efficacy observed on day 6 after infection was shown at 10% oxyresveratrol in cream applied three times daily. The frequency of application of 10% oxyresveratrol cream at three, four and five times daily was as effective as that of 5% ACV cream applied five times daily (P > 0.05). These results demonstrated that topical administration of oxyresveratrol in novel cream vehicle reduced the concentration of oxyresveratrol to 10% and was suitable for cutaneous HSV infection.
authors.affiliation: Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Patumwan, Bangkok 10330, Thailand. lvimolma@chula.ac.th
authors.forename: Vimolmas
authors.initials: V
authors.lastname: Lipipun
authors.forename: Pattaraporn
authors.initials: P
authors.lastname: Sasivimolphan
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Tohru
authors.initials: T
authors.lastname: Daikoku
authors.forename: Boonchoo
authors.initials: B
authors.lastname: Sritularak
authors.forename: Garnpimol
authors.initials: G
authors.lastname: Ritthidej
authors.forename: Kittisak
authors.initials: K
authors.lastname: Likhitwitayawuid
authors.forename: Pornpen
authors.initials: P
authors.lastname: Pramyothin
authors.forename: Masao
authors.initials: M
authors.lastname: Hattori
authors.forename: Kimiyasu
authors.initials: K
authors.lastname: Shiraki
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use; D000279:Administration, Cutaneous; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D031622:Artocarpus / Q000737:chemistry; D002522:Chlorocebus aethiops; D004305:Dose-Response Relationship, Drug; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy*; D018259:Herpesvirus 1, Human / Q000187:drug effects* / Q000254:growth & development; D018258:Herpesvirus 2, Human / Q000187:drug effects* / Q000254:growth & development; D020128:Inhibitory Concentration 50; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests / Q000379:methods; D010936:Plant Extracts / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013267:Stilbenes / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D014709:Vero Cells; D010948:Viral Plaque Assay
chemical_list: D000998:Antiviral Agents; D010936:Plant Extracts; D013267:Stilbenes; C034912:puag-haad; D000212:Acyclovir